(b).
Diagnostic performance of four markers in detecting AFP-negative or AFP-positive patients with early-stage HCC
| Marker | Early-HCC vs LC+ CHB+HC
|
Early-HCC vs LC+ CHB
|
Early-HCC vs LC
|
|||
|---|---|---|---|---|---|---|
| AUC (95% CI)a | SEN at 90% SPE (95% CI)b | AUC (95% CI)a | SEN at 90% SPE (95% CI)b | AUC (95% CI)a | SEN at 90% SPE (95% CI)b | |
| AFP-positivec | ||||||
| AFP-L3 | 0.85 (0.61–100.0) | 75.4 (25.0–100.0) | 0.83 (0.62–1) | 74.0 (33.3–100.0) | 0.83 (0.63–1) | 73.7 (33.3–100.0) |
| DCP | 0.72 (0.63–0.90) | 41.4 (26.7–83.4) | 0.70 (0.62–0.88) | 42.6 (28.6–83.3) | 0.68 (0.62–0.87) | 37.1 (25.0–76.5) |
| SCCA | 0.45 (0.33–0.60) | 7.9 (0–22.2) | 0.47 (0.33–0.64) | 7.0 (0–33.3) | 0.47 (0.33–0.64) | 7.0 (0–33.3) |
| CENPF | 0.54 (0.40–0.84) | 12.2 (0–50.0) | 0.44 (0.21–0.73) | 4.9 (0–25.0) | 0.44 (0.21–0.73) | 4.9 (0–25.0) |
| AFP-negativec | ||||||
| AFP-L3 | 0.47 (0.44–0.54) | 9.2 (0–14.3) | 0.46 (0.43–0.53) | 5.4 (0–13.3) | 0.46 (0.43–0.53) | 9.4 (0–13.3) |
| DCP | 0.69 (0.61–0.82) | 48.0 (28.6–70.0) | 0.69 (0.59–0.82) | 39.0 (29.4–68.8) | 0.66 (0.60–0.81) | 36.7 (23.8–64.7) |
| SCCA | 0.49 (0.35–0.62) | 10.8 (0–31.3) | 0.46 (0.35–0.60) | 7.2 (0–33.3) | 0.46 (0.35–0.60) | 7.2 (0–33.3) |
| CENPF | 0.45 (0.30–0.67) | 9.0 (0–22.2) | 0.44 (0.32–0.60) | 6.3 (0–30.0) | 0.44 (0.32–0.60) | 6.3 (0–30.0) |
Note:
a
AUC was adjusted for potential overfitting by the .632+ bootstrap method.
b
.632+ bootstrap adjusted sensitivity at cutoffs yielding 90% specificity.
c
The threshold is 20 ng/mL to define the positivity of AFP.
Abbreviations: AFP, alpha-fetoprotein; AFP-L3, lens culinaris agglutinin-reactive AFP; AUC, area under the curve; CENPF, centromere protein F autoantibody; CHB, chronic hepatitis B virus infection; DCP, des-gamma-carboxyprothrombin; HC, healthy control; HCC, hepatocellular carcinoma; LC, liver cirrhosis; SCCA, squamous cell carcinoma antigen; SEN, sensitivity; SPE, specificity.